Companies › Priovant Therapeutics
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Immunology, Ophthalmology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Brepocitinib JAK1 inhibitor | JAK1 | Phase 3 | Uveitis, Posterior; Lichen Planopilaris; Cutaneous Sarcoidosis | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06431373 | Brepocitinib | Phase 3 | Uveitis, Posterior | Ophthalmology | Feb 2028 |
| NCT07532603 | Brepocitinib | Phase 2 | Lichen Planopilaris | Immunology | Dec 2028 |
| NCT06978725 | Brepocitinib | Phase 2 | Cutaneous Sarcoidosis | Immunology | Dec 2028 |
Sun Pharma Japan Alfasigma Triple Hair ReGenTree Laboratorios Sophia S.A de C.V.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.